CAMK2G and heart failure: IC50 of ~3 μM (AC3I) and 40 nM (AIP). Cardiac specific transgenic models shown to effectively attenuate hypertrophic remodeling, heart failure (HF), and arrhythmias. Limitations: Comprehensive screening of off-targets would be necessary for translational approaches. Existing screens show specificity for CaMKII; however, all isoforms are targeted with equal potency, mandating cardiac specific expression. Bioavailability and cell permeation nonexistent without use of viral vector delivery or potential use of novel nanoparticle delivery.